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Background: Depression is highly prevalent among patients with Chronic Obstructive Pulmo-
nary Disease (COPD). The relationship of depression with systemic inflammation in COPD re-
mains unknown. The objective of this observational study was to compare depression scores
at baseline and after 36 months follow-up between COPD patients with persistent systemic
inflammation (PSI) and never inflamed patients (NI) in the ECLIPSE cohort.
Methods: The ECLIPSE study included 2164 COPD patients. Parameters assessed at baseline
and at 36 months follow-up included: demographics, clinical characteristics and symptomsc inflammation; NI, never inflamed patients.
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of depression (Center for Epidemiologic Studies of Depression, CES-D). Patients classified as NI
had zero and patients with PSI had 2 inflammatory biomarkers (white blood cell count, hsCRP,
IL-6, and fibrinogen) in the upper quartile, at baseline and 12 months later.
Findings: 350 patients (29.1%) were NI and 131 patients (10.9%) had PSI. At baseline, mean
CES-D score was higher in patients with PSI than in NI patients (11.7 (8.6) vs. 9.2 (8.9) points,
p Z 0.01). Differences were not confirmed after adjustment for possible confounders (b (95%
CI) Z 0.02 (3.87 to 15.29), adjusted p Z 0.98). At 36 months follow-up, CES-D scores were
comparable in PSI and NI patients (12.2 (9.3) vs. 10.5 (9.0) points, pZ 0.08) as were their tem-
poral changes (0.5 (8.3) vs. 1.3 (7.9) points, p Z 0.30).
Conclusion: The ECLIPSE study does not support a strong relationship between PSI and symp-
toms of depression at baseline and after 36 months follow-up in COPD.
Funding: The study was sponsored by GlaxoSmithKline.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Although Chronic Obstructive Pulmonary Disease (COPD) is
characterized by persistent and often progressive airflow
limitation, comorbidities contribute to the severity of the
disease [1]. Depression is a frequent COPD comorbidity
which is often underdiagnosed and undertreated [2], but
clinically relevant. For instance, depression scores are
worse among COPD patients with frequent exacerbations
[3], and mortality is higher in patients hospitalized because
of an acute exacerbation and clinically relevant symptoms
of depression [4]. A recent systematic review showed a
bidirectional relationship between COPD and depression
where COPD increases the risk of developing depression,
and depression is associated with worse outcomes in COPD
[5].
The pathobiology of depression in COPD is unclear.
Previous cross-sectional analysis of the ECLIPSE (‘Evalua-
tion of COPD Longitudinally to Identify Predictive Surrogate
End-points’) study identified several clinical determinants
of depression (as assessed by the Center for Epidemiologic
Studies of Depression Scale (CES-D)), such as a poorer
health state, younger age, female sex, stage of airflow
limitation, and current smoking status [6]. In the ECLIPSE
study, the serum levels of a number of inflammatory bio-
markers, including fibrinogen, high-sensitivity C-reactive
protein (hsCRP), surfactant protein-D (SP-D), chemokine
ligand-18 (CCL-18), interleukin-6 (IL-6), interleukin-8 (IL-8),
and tumor necrosis factor alpha (TNF-a), were not corre-
lated with baseline depression scores, but club (clara) cell
protein-16 (CC-16) levels were lower in patients with clin-
ically relevant symptoms of depression [6]. Other studies,
however, have suggested a relationship between TNF-a, or
its soluble receptor 1 (sTNFR-1), and depression scores in
patients with COPD [7,8]. Also, in other chronic diseases a
relationship has been suggested between systemic inflam-
mation and depression. For example, previous studies
showed a relationship between inflammatory biomarkers
and symptoms of depression in patients with type 2 dia-
betes or heart failure [9,10]. In addition, a recent study in
mice showed that peripheral inflammation is associated
with remote global gene expression changes in the brain
and this may explain how inflammation may contribute tothe development of symptoms of depression in patients
with chronic diseases [11].
A recent ECLIPSE publication showed that about a third
of COPD patients did not show evidence of systemic
inflammation, either at baseline or one year later (‘never-
inflamed’ (NI)), whereas 16% had evidence of persistent
systemic inflammation (PSI) over one year [12]. Impor-
tantly, patients with PSI had more comorbidities and higher
all-cause mortality and exacerbation rates during follow-up
than NI ones [12]. However, the relationship between PSI
and symptoms of depression among patients with COPD has
not been explored. We hypothesized that PSI is related to
depression in COPD. To test this hypothesis, we compared
depression scores at baseline and after 36 months follow-up
in NI and PSI COPD patients in the ECLIPSE cohort.Material and methods
Study design
The present study is a secondary analysis of the ECLIPSE
study (Clinicaltrials.gov identifier NCT00292552; GSK study
code SCO104960), a multicenter, longitudinal, controlled,
observational study, conducted in 12 countries whose
methodology has been published in detail elsewhere [13].
Participants were assessed at baseline, three and six
months, and then every six months for 36 months.Study population and ethics
The ECLIPSE study recruited 2164 patients with COPD [14].
Patients were between 40 and 75 years of age, with a
baseline post-bronchodilator forced expiratory volume in
the first second (FEV1) below 80% of the predicted value,
and a FEV1/forced vital capacity (FVC) ratio below or equal
to 0.7 and a smoking history of 10 or more pack years.
Patients were clinically stable, defined by the absence of
any COPD exacerbation within four weeks preceding
enrollment [13]. The current analysis is limited to patients
with complete data on the primary outcome variables and
possible confounders of the relationship between
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131 patients with PSI).
The ECLIPSE study complies with the Declaration of
Helsinki and Good Clinical Practice guidelines. Approval
from the Medical Ethics Committees or Institutional Review
Boards was obtained from all participating centers. All
patients gave written informed consent [13].
Measurements
Demographic characteristics (age, sex, race, educational
level) and clinical characteristics (body mass index (BMI),
smoking status, number of pack years, long-term oxygen
use, BODE index [15], history of depression, and antide-
pressant use) were recorded at baseline and during follow-
up visits. Spirometry and the six-minute walk tests were
performed according to international guidelines [16,17].
The number of exacerbations during 36 months follow-up
was recorded using monthly phone calls and scheduled
study visits [13].
Symptoms of depression during the previous week were
measured at baseline and after 36 months follow-up using
the CES-D, a self-administered questionnaire consisting of
20 items [18]. Each item is scored on a four-point scale
ranging from ‘rarely or none of the time’ to ‘most or all of
the time’. Total score ranges from 0 (best) to 60 (worst)
points. A score of 16 points and higher indicates clinically
relevant symptoms of depression (sensitivity 0.73; speci-
ficity 0.84) [18]. Testeretest reliability is estimated at 0.71
[19].
Severity of dyspnea was measured using the modified
Medical Research Council dyspnea scale (mMRC) at baseline
and every year [20]. Disease-specific health status was
measured using the St. George Respiratory Questionnaire
for COPD patients (SGRQ-C) at baseline and every year.
Total scores range from 0 (no impairment) to 100 (worst
possible health status) points [21].
Peripheral venous blood was collected in the morning,
after fasting overnight, at baseline and at one year follow-
up to measure biomarkers. Details of biomarkers mea-
surement have been published before [12]. PSI was defined
as the presence, both at baseline and after one year follow-
up, of two or more of the following biomarkers in the upper
quartile: white blood cell (WBC) count, hsCRP, IL-6, and
fibrinogen [12]. Patients were classified as NI when none of
these biomarkers was in the upper quartile at baseline or
after one year follow-up [12].
Statistical analysis
Results are presented as mean (SD), median (SD), and/or
proportions, as appropriate. Demographics, clinical char-
acteristics and CES-D scores were compared between NI
patients and patients with PSI. Chi square tests were used
for categorical variables. Independent sample T tests were
used for normally distributed continuous variables, while
ManneWhitney U tests were used for continuous variables
that were not normally distributed. Changes between
baseline and 36 months in CES-D scores were compared
using paired T-tests, after stratification for presence of PSI.
Linear regression models were used to examine theassociation between PSI and CES-D score at baseline and 36
months, where CES-D score was the dependent variable, PSI
the independent one and a number of patient character-
istics previously shown in the literature to have a rela-
tionship with symptoms of depression in patients with COPD
were considered covariates. The latter include: age
[4,6,22,23], sex [6,24], FEV1 (% pred.) [6], BMI [2,4,24],
mMRC score [2,24], SGRQ total score [22], six-minute
walking distance [25], smoking status [6], educational
level [23] and number of exacerbations [3] (only in the
model with CES-D score at 36 months as dependent vari-
able). Analyses were done using SPSS v.19.0. A two-sided
level of significance was set at p  0.05.
Role of the funding source
GlaxoSmithKline had a role in study design; in the collec-
tion, analysis, and interpretation of data; in the writing of
the report; and in the decision to submit the paper for
publication.
Results
Patient population
ECLIPSE recruited 2164 patients with COPD. Of these, 211
died during 36 months follow-up (9.8%), 286 (13.2%) with-
drew because of other reasons, and 466 (21.5%) had
incomplete data on the primary outcome variables or
possible confounders of the relationship between PSI and
depression either at baseline or 36 months later. Hence,
131 patients (10.9%) with PSI and 350 NI patients (29.1%)
were finally included in the current analysis (total 481 pa-
tients, 22.2% of the original cohort).
Patient characteristics stratified by systemic
inflammation
Table 1 shows that, compared to NI patients, those with PSI
had higher BMI, lower FEV1, were more often current
smokers, were more likely to have been prescribed long-
term oxygen therapy, had worse exercise capacity, more
dyspnea, worse disease-specific health status and higher
BODE index. They also experienced more exacerbations
during follow-up than NI patients (median (IQR): 3.0
(1.0e5.0) vs. 2.0 (0.0e4.0), p < 0.001).
Symptoms of depression at baseline in NI and PSI
patients
At baseline, mean CES-D score was higher in patients with
PSI than in NI patients (pZ 0.01) (Table 2). However, after
adjustment for possible confounders in linear regression
analysis, CES-D scores were comparable between patients
with and without PSI (b (95% CI) Z 0.02 (3.87 to 15.29),
adjusted pZ 0.98) (Table 3). By contrast, mMRC score and
SGRQ total score emerged as significant determinants of
depression in COPD. Higher mMRC score was related with
lower CES-D score, while higher SGRQ total score was
related with higher CES-D score. When the same analysis
Table 1 Baseline patient characteristics stratified for presence of PSI.
PSI
(n Z 131)
NI
(n Z 350)
Unadjusted p-value
Age (years) 63.8 (6.4) 62.9 (6.9) 0.23
Male 99 (75.6%) 218 (62.3%) 0.01
Caucasian 129 (98.5%) 343 (98.0%) 1.0
Educational level high school or more 35 (26.7%) 83 (23.7%) 0.57
Body mass index (kg/m2) 29.2 (6.5) 25.8 (4.8) <0.001
Post bronchodilator FEV1 (L) 1.3 (0.4) 1.5 (0.5) <0.001
Post bronchodilator FEV1 (% pred.) 45.7 (13$9) 52.3 (15.2) <0.001
Post bronchodilator FEV1/FVC 0.45 (0.11) 0.46 (0.11) 0.36
Current smoker 61 (46.6%) 102 (29.1%) <0.001
Pack years (number)a 52.2 (28.2) 44.2 (25.2) 0.004
Long-term oxygen therapy 13 (9.9%) 11 (3.1%) 0.002
6 min walking distance (m) 360.9 (113.3) 422.8 (107.2) <0.001
mMRC score (points) 1.9 (1.0) 1.3 (0.9) <0.001
SGRQ-C total score (points) 56.4 (19.1) 42.0 (18.7) <0.001
BODE index (points) 3.4 (1.9) 2.3 (1.8) <0.001
Data presented as mean (SD) or number (%). Abbreviations: FEV1 Z Forced Expiratory Volume in the first second; FVC Z Forced Vital
Capacity; mMRC Z modified Medical Research Counsel dyspnea scale; NI Z No Inflammation; PSI Z Persistent Systemic Inflammation;
SGRQ-C Z St. George Respiratory Questionnaire for COPD patients.
a Non-parametric statistical tests were used because of skewed data.
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(n Z 585), irrespective of the fact that some patients died
or withdrew from the study during follow-up, baseline CES-
D scores were also comparable between NI and PSI patients
(b (95% CI) Z 0.63 (0.95 to 2.20), adjusted p Z 0.44).
Finally, history of depression and antidepressant use at
baseline was similar in NI patients and patients with PSI
(p Z 0.84 and p Z 0.44, respectively) (Table 2).Changes in symptoms of depression during 36
months follow-up
Mean CES-D scores remained unchanged after 36 months in
PSI patients (p Z 0.50). Mean CES-D scores increased
slightly but significantly in NI patients (p Z 0.002). At 36
months a trend was suggested towards higher CES-D scores
in patients with PSI compared to NI patients (p Z 0.08)Table 2 CES-D scores, history of depression, and antidepressan
PSI
(n Z 131)
Baseline CES-D score (points) 11.7 (8.6)
CES-D score at 36 months (points) 12.2 (9.3)
Change in CES-D score (points) 0.5 (8.3)
Incident depressiona 18 (13.7%)
Recovery from depressionb 14 (10.7%)
History of depression 16 (12.2%)
Antidepressant use at baseline 17 (13.0%)
Data presented as mean (SD) or number (%). Abbreviations: CES-D
Inflammation; PSI Z Persistent Systemic Inflammation.
a Incident depression Z Change CES-D score from <16 points to 1
b Recovery from depression Z Change CES-D score from 16 points(Fig. 1). This was not confirmed by linear regression analysis
after correction for the aforementioned possible con-
founders (b (95% CI) Z 0.66 (2.38 to 1.06), adjusted
p Z 0.45). In addition, there were no statistically signifi-
cant differences in mean changes in CES-D scores between
baseline and 36 months between patients with PSI and NI
patients (pZ 0.30). Finally, the proportion of patients who
developed clinically relevant symptoms of depression or
recovered from clinically relevant symptoms of depression
was comparable between patients with PSI and NI patients
(p Z 0.66 and p Z 0.15, respectively, Table 2).Discussion
The key findings of this observational study in 481 patients
with COPD are that: (1) the presence of PSI is not related to
clinically relevant symptoms of depression at baseline,t use stratified for presence of PSI: univariate analyses.
NI
(n Z 350)
Unadjusted p-value
9.2 (8.9) 0.01
10.5 (9.0) 0.08
1.3 (7.9) 0.30
41 (11.7%) 0.66
22 (6.3%) 0.15
47 (13.4%) 0.84
35 (10.0%) 0.44
Z Center for Epidemiologic Studies Depression scale; NI Z No
6 points.
to <16 points.
Table 3 Relationship between baseline CES-D score and presence of PSI: linear regression analysis.
Beta (95% CI) Adjusted p-value
Primary predictor
PSI (ref: no) 0.02 (3.87 to 15.29) 0.98
Covariates
Age 0.09 (0.20 to 0.02) 0.11
Sex (ref: female) 1.25 (2.82 to 0.33) 0.12
Educational level (ref: less than high school) 1.38 (3.05 to 0.29) 0.11
Body mass index 0.01 (0.15 to 0.14) 0.91
Post bronchodilator FEV1 (% pred.) 0.04 (0.02 to 0.09) 0.18
Current smoker (ref: non-smoker) 0.22 (1.37 to 1.80) 0.79
6 min walking distance 0.00 (0.01 to 0.01) 0.67
mMRC score 1.27 (2.24 to 0.29) 0.01
SGRQ-C total score 0.25 (0.20e0.30) <0.001
n Z 481. r2 Z 0.24, p < 0.001. Abbreviations: see legend Table 1. CI Z Confidence Interval.
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after correction for potential confounders; and, (2) the
main determinants of symptoms of depression in this pop-
ulation were dyspnea and disease-specific health status.
Overall, these results do not support our working hypothesis
but contribute to better understand the determinants of
depression in COPD, a frequent and clinically relevant co-
morbidity in these patients.
The present study found that mean CES-D scores
increased significantly (þ1.3 points) in NI patients after 36
months, while mean CES-D scores remained unchanged
after 36 months in PSI patients. To date, a minimal clinical
important difference for the CES-D remains unknown,
which makes it difficult to interpret these findings. How-
ever, a French population study showed mean CES-D
changes between 0.4 and þ2.5 points over three years
[26], while another study among healthy individuals found a
decrease of 1.2 points after one year [27]. Moreover, pre-
vious authors studying an intervention in primary care pa-
tients with a newly diagnosed depression defined a change
of 3.6 points over 6 months as a relevant change [28].
Therefore, the clinical relevance of the statistically sig-
nificant change in CES-D score over three years among NI
patients seems limited.Figure 1 CES-D scores (Mean, SEM) stratified for the pres-
ence of PSI. Abbreviations: CES-D Z Center for Epidemiologic
Studies Depression scale; NI Z No Inflammation;
PSI Z Persistent Systemic Inflammation. n Z 481.Previous studies
A number of previous studies have investigated
potential general mechanisms linking systemic inflamma-
tion and depression, including a direct effect on neuronal
function [29], the activation of the hypothal-
amusepituitaryeadrenal axis [29] and/or oxidative stress
[30]. Besides, a study in the general population suggested
that there may be a relationship between systemic
inflammation and depression subtypes, because the sub-
group of younger adults with atypical major depressive
disorder had higher CRP levels [31].
In the context of COPD, three previous studies are worth
noting. Firstly, Al-shair et al. found a positive correlation
between TNF-a (but not other inflammatory markers like
CRP, TNF-a-R1, TNF-a-R2, and IL-6) and the BASDEC
depression score in stable patients with moderate COPD,
after adjusting for potential confounders [7]. In our study
we did not include TNF-a in the definition of PSI because it
may be a marker of smoking rather than COPD [12]. How-
ever, a previous ECLIPSE publication did not find any rela-
tionship between CES-D scores and TNF-a [6]. Secondly,
Eagan et al. showed a relationship between TNFR-1 and
depression requiring treatment in patients with COPD, after
correction for possible confounders [8]. We did not include
TNFR-1 in the definition of PSI and, in fact, a previous
ECLIPSE analysis showed no difference in TNFR-1 between
persons with or without COPD [32]. Thirdly, in line with our
findings, Thomsen et al. showed no relationship between
the combination of CRP, fibrinogen, and leukocyte count at
baseline and hospital admission because of depression
within five year follow-up after adjustment for potential
confounders among 8571 subjects with COPD identified
from a Danish general population sample [33].
Interpretation of findings
Although poorly understood, mechanisms underlying
depression in COPD are likely multifactorial and may
include biological, disease-related and social factors [34].
The former include, among others, genetic factors that may
drive nicotine addiction and COPD development [34] and
1652 D.J.A. Janssen et al.poor brain oxygenation, particularly in the periventricular
and subcortical regions [35]. COPD itself can equally lead to
symptoms of depression [35] through, for instance, limita-
tions in daily activities [34]. Finally, social factors may also
be important since poor family support appears to be
associated with depression in COPD [36]. The relationship
between depression and disease-specific health status in
COPD is well-known [2,22]. We were unable to find a rela-
tionship between PSI and depression, although we found a
univariate relationship between PSI and disease-specific
health status. Our study confirms the important relation-
ship between symptoms of depression and the impact of
COPD. Indeed, symptoms and disease-specific health status
are more important determinants of depression than bio-
logical factors such as FEV1 or PSI. Comparable results were
found among patients with rheumatoid arthritis. A study by
Low et al. [37] suggested a relationship between symptoms
of depression and CRP in women with rheumatoid arthritis.
However, after adjustment for pain and disability this
relationship was no longer significant. This emphasizes the
importance of interventions aimed to reduce the impact of
chronic diseases. For instance, pulmonary rehabilitation
has been shown to improve symptom burden, disease-
specific health status, exercise tolerance, the ability to
cope with COPD as well as symptoms of depression [38].
Potential limitations
Our study has several potential limitations that deserve
comment. Firstly, we only included patients who completed
at least one year follow-up. Therefore, it is unknown if our
observations canbeapplied topatientswith less thanoneyear
survival. Secondly, symptoms of depression were assessed
using the CES-D that measures the presence of clinically
relevant symptoms of depression in the previous week. This
may limit the identification of a relationship between symp-
toms of depression and PSI, albeit it is of note that we did not
find either a relationship between PSI and history of depres-
sion or use of antidepressants. Third, inflammatory bio-
markers were only measured at baseline and after one year.
Therefore, stability of PSI in this cohort is unknown. Finally,
our study classified subjects as persistently inflamed vs. non-
inflamed using an index we previously have related to other
outcomes in COPD. Our results do not exclude the possibility
that a different pattern of inflammation is related to
depression prevalence or progression in COPD.
Conclusions and implications for future studies
Our study is the first to explore the relationship between
symptoms of depression in COPD patients and PSI, both at
baseline and after one year follow-up. Our findings do not
support a strong relationship with PSI but, given that
depression is not a homogenous entity [34], before
completely rejecting our hypothesis, it might be reasonable
to explore the relationship between PSI and several sub-
types of major depressive disorders in COPD. On the other
hand, our longitudinal results confirm previous cross-
sectional analysis that identified symptoms and impaired
health status as major determinants of symptoms of
depression. This emphasizes the importance of therapeuticinterventions aimed to reduce the impact of COPD, such as
pulmonary rehabilitation [38].
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